News
Public · Published
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Novartis said third-quarter net sales grew 4% and core operating income rose 10%, with the core operating income margin at 41.6%, up 2 percentage points. It raised full-year 2026 core operating income guidance to in line to low single-digit growth.
Published:
Updated:
What happened
Novartis said third-quarter net sales grew 4% and core operating income rose 10%, with the core operating income margin at 41.6%, up 2 percentage points. It raised full-year 2026 core operating income guidance to in line to low single-digit growth.
Confirmed
Global impact / market context
A higher core margin means Novartis keeps more profit from each sale after excluding certain items, which supports earnings and cash generation. The raised core operating income guidance signals management expects profit to hold up better than previously guided.
Analyst inference
Novartis is balancing growth from priority brands against a large reported profit decline from a partial impairment, which is a writedown in the value of an asset. Investors weigh that reported weakness against stronger core profit and cash flow.
Analyst inference
What to watch
- Q3 free cash flow, which is cash available after spending, was USD 5.1 billion and fell in USD terms, so watch whether cash generation recovers in the fourth quarter. Confirmed
- Watch whether Novartis converts the raised core operating income guidance into reported profit, given the impairment of the del-desiran asset dragged operating income lower. Proposed
- Watch sales of priority brands such as Kisqali, Kesimpta, Scemblix, Leqvio and Cosentyx, since their growth carried the quarter and offsets weaker parts of the portfolio. Analyst inference